MEDPACE HOLDINGS INC (MEDP)
Sector: Health Care
2026 Annual Meeting Analysis
MEDPACE HOLDINGS INC · Meeting: May 15, 2026
Directors FOR
5
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Carley has served since 2016 and MEDP's 3-year price return of +170.6% outperforms the peer group median by +184.0 percentage points, far exceeding the 65-percentage-point threshold required to trigger an against vote; no overboarding, attendance, or independence concerns noted.
Gwadry-Sridhar joined in January 2023, placing her tenure at just over 24 months, and MEDP's strong outperformance versus peers means the TSR trigger does not apply; her background in clinical research and real-world evidence is directly relevant to a clinical contract research organization.
Kraft has served since 2016 and the company's 3-year outperformance versus the peer group (+184.0 percentage points) is well above the 65-percentage-point threshold needed to trigger a negative vote; he is a sitting CFO at a private company with no overboarding concern.
Troendle is the CEO-founder and has served since 1992; MEDP's 3-year price return of +170.6% outperforms the disclosed peer group median by +184.0 percentage points, far exceeding the 65-percentage-point threshold required for a negative vote, so the TSR trigger does not apply to him as a director.
Zander joined in July 2024 and has been on the board for less than 24 months, making her exempt from the TSR trigger under our policy; her expertise in pathology and laboratory medicine is relevant to the company's clinical research business.
All five nominees — three Class I directors (Carley, Gwadry-Sridhar, Kraft) and two Class III directors (Troendle, Zander) — receive a FOR vote. MEDP's 3-year price return of +170.6% outperforms the disclosed peer group median by +184.0 percentage points, well above the 65-percentage-point threshold required to trigger a negative vote; no overboarding, attendance, or independence issues were identified for any nominee.
Say on Pay
✓ FORCEO
August J. Troendle
Total Comp
$11,443,766
Prior Support
89%%
CEO total compensation of approximately $11.4 million consists almost entirely of variable pay (a $492,350 cash bonus tied to EBITDA and revenue targets, and roughly $10 million in stock option awards), reflecting a strong performance orientation; the prior say-on-pay vote received over 89% support, well above the 70% threshold that would require a response, and the company has a meaningful clawback policy in place. The company's 3-year total shareholder return of +170.6% dramatically outperforms the peer group median of -13.4%, providing strong pay-for-performance alignment — above-benchmark incentive pay is clearly justified by superior shareholder outcomes. The compensation program avoids problematic features such as excise tax gross-ups, guaranteed bonuses, or stand-alone change-of-control agreements, and the company's own disclosure indicates aggregate NEO pay is below the 50th percentile of peers.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
24 yrs
Audit Fees
$1,422,000
Non-Audit Fees
$36,900
Non-audit fees (tax fees of $34,900 plus other fees of $2,000 = $36,900) represent only about 2.6% of audit fees ($1,422,000), well below the 50% threshold that would raise independence concerns; Deloitte's tenure of approximately 24 years is just under the 25-year threshold that would trigger a negative vote; Deloitte is a Big 4 firm appropriate for a $14 billion market-cap company, and no material restatements were identified.
Stockholder Proposals
3 proposals submitted by shareholders
Proposal 5
Amendment of Certificate of Incorporation to Remove Supermajority Voting Requirements
This is a board-proposed charter amendment that would eliminate the current requirement for a 66⅔% supermajority vote on key governance matters — including removing directors and amending core charter provisions — replacing it with a simple majority vote standard under Delaware law. Removing supermajority thresholds is a straightforward governance improvement: it gives ordinary shareholders a more meaningful voice in corporate decisions and is widely recognized as a best practice. The board acted in direct response to significant stockholder support at the 2025 annual meeting, making this a clear case where supporting the proposal aligns shareholder rights with long-term corporate accountability.
Proposal 6
Amendment of Certificate of Incorporation to Remove the Limitation on Stockholders Calling Special Meetings of Stockholders
This board-proposed charter amendment moves the company from a position of zero stockholder ability to call special meetings — the current charter reserves that right solely for the board — to allowing shareholders who collectively own at least 25% of shares continuously for one year to request a special meeting. This is a meaningful improvement in shareholder rights from the current baseline of no right at all, even if the 25% threshold is more restrictive than some investors might prefer. A competing shareholder proposal (Proposal 7) seeks a 10% threshold without a holding period requirement, but the board's proposal is a genuine governance step forward and should be supported; shareholders can advocate for a lower threshold in future years.
Proposal 7
Advisory Vote on a Stockholder Proposal: Give Shareholders an Ability to Call for a Special Shareholder Meeting
This proposal asks the board to allow shareholders owning as little as 10% of shares — with no minimum holding period — to call a special meeting, and would prohibit any holding-period requirement. While the underlying goal of giving shareholders a voice is legitimate, the company is simultaneously putting a meaningful special meeting right to a binding vote via Proposal 6, which grants access to shareholders owning 25% for one year. Voting FOR Proposal 7 while also supporting Proposal 6 would send a contradictory signal on the appropriate threshold, and the 10% threshold with no holding requirement creates real risk that a small group of short-term shareholders could force costly special meetings that do not reflect the interests of the broader shareholder base. Since the company's Proposal 6 substantively addresses the core governance concern, Proposal 7 is unnecessary at this meeting.
Overall Assessment
The 2026 Medpace Holdings annual meeting presents a generally shareholder-friendly ballot: all five director nominees receive a FOR vote supported by exceptional 3-year total shareholder return of +170.6% that dramatically outperforms the peer group; the auditor ratification, say-on-pay, and both board-proposed charter amendments (removing supermajority requirements and granting a new special meeting right) all warrant support. The lone AGAINST vote is on the individual stockholder's competing special meeting proposal (Proposal 7), which is rendered unnecessary by the board's own binding Proposal 6 that already grants stockholders a meaningful — if more restrictive — right to call special meetings.
Compensation Peer Group
11 companies disclosed in 2026 proxy filing